Disseminated disease

Lundquist Institute Start-Up Vitalex Biosciences Awarded Grant from NIAID/NIH

Retrieved on: 
Tuesday, April 25, 2023
Infection, GLP, Charles H. Lundquist College of Business, Fungal infection, TLI, SBIR, National Institute of Allergy and Infectious Diseases, CMC, COVID-19, Encephalitis, Mucormycosis, Doctor of Philosophy, Bangladesh Technical Education Board, Mab, Disseminated disease, Investigational New Drug, Patient, Mortality, NIAID, Immunodeficiency, Creative Biolabs, IND, Disease, Pharmaceutical industry, Chemistry

Los Angeles, April 25, 2023 (GLOBE NEWSWIRE) -- The Lundquist Institute (TLI) start-up company, Vitalex Biosciences, has been awarded an SBIR Phase 2 grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health.

Key Points: 
  • Los Angeles, April 25, 2023 (GLOBE NEWSWIRE) -- The Lundquist Institute (TLI) start-up company, Vitalex Biosciences, has been awarded an SBIR Phase 2 grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health.
  • The grant is for Vitalex’s VX-01, a monoclonal antibody (mAB) program targeting the debilitating indication of the fungal disease, mucormycosis.
  • Vitalex Biosciences is in residence at BioLabs at The Lundquist, a state-of-the-art incubator space for life science start-ups.
  • “We are very proud to have received this prestigious award from NIAID,” said Ashraf Ibrahim, PhD, an Investigator at The Lundquist Institute and the founder and CEO of Vitalex Biosciences.

Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration

Retrieved on: 
Friday, January 6, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cancer, ICIS, Euronext Paris, International Cancer Genome Consortium, ANSM, Neoplasm, Patient, Tumor microenvironment, CTA, Disseminated disease, Medication, Lysis, Large-cell lung carcinoma, IL-12, IV, National Agency for Food and Drug Administration and Control, Safety, NSCLC, Pharmaceutical industry, Vaccine

It has been engineered to express human IL-12, a cytokine that triggers a powerful antitumor immune response, and a full length anti-CTLA4 antibody.

Key Points: 
  • It has been engineered to express human IL-12, a cytokine that triggers a powerful antitumor immune response, and a full length anti-CTLA4 antibody.
  • TG6050 has been designed to be administered intravenously, a route of administration that has been demonstrated to be safe and feasible with an Invir.IO™ based OV.
  • Intratumoral injection, where the drug is injected directly into the tumor, is currently the only approved route of administration for an oncolytic virus.
  • Intravenous administration addresses a broader range of patients with solid tumors who are not suitable for intratumoral administration.